Abstract
Responding to a negative assessment by Daniel W. Sigelman of the social impact of current efforts to promote competition in the medical marketplace, Blumstein argues that, since the competitive strategy is designed to rationalize health care delivery, it should be evaluated independently of the issue of financing health care for the poor. (KIE abstract)
